Abstract
BACKGROUND Turner syndrome (TS) with leukemia is a complicated clinical condition. The clinical course and outcome of these patients are poor, so the treatment and prognosis of TS with hematological malignancies deserve our attention. CASE SUMMARY Here, we report a case of a 20-year-old woman diagnosed with TS, primary myelofibrosis (PMF), cirrhosis, and an ovarian cystic mass. This is the first report on the coexistence of TS and PMF with the MPL and SH2B3 mutations. The patient was diagnosed with cirrhosis of unknown cause, splenomegaly and severe gastroesophageal varices. Additionally, an ovarian cystic mass caused the patient to appear pregnant. The patient was treated with the JAK2 inhibitor-ruxolitinib according to peripheral blood cells, although myelofibrosis was improved, the splenomegaly did not reduce. Moreover, hematemesis and melena occasionally occurred. CONCLUSION Ruxolitinib may clearly reduce splenomegaly. Though myelofibrosis was improved, cirrhosis and splenomegaly in this case continued to worsen. Effective treatment should be discussed.
Author supplied keywords
Cite
CITATION STYLE
Xu, L. W., Su, Y. Z., & Tao, H. F. (2022). Turner syndrome with primary myelofibrosis, cirrhosis and ovarian cystic mass: A case report. World Journal of Clinical Cases, 10(9), 2931–2937. https://doi.org/10.12998/wjcc.v10.i9.2931
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.